Seelos Total Liabilities from 2010 to 2024
| SEEL Stock | USD 0.33 0.01 2.94% |
Check Seelos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Seelos main balance sheet or income statement drivers, such as Depreciation And Amortization of 54.1 K, Interest Expense of 71.2 K or Selling General Administrative of 8.7 M, as well as many exotic indicators such as Price To Sales Ratio of 3.38, Dividend Yield of 0.0038 or Days Sales Outstanding of 104. Seelos financial statements analysis is a perfect complement when working with Seelos Therapeutics Valuation or Volatility modules.
Seelos | Total Liabilities |
About Seelos Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Seelos Therapeutics income statement, its balance sheet, and the statement of cash flows. Seelos Therapeutics investors use historical funamental indicators, such as Seelos Therapeutics's Total Liabilities, to determine how well the company is positioned to perform in the future. Although Seelos Therapeutics investors may use each financial statement separately, they are all related. The changes in Seelos Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Seelos Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Seelos Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Seelos Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seelos Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seelos Therapeutics' short interest history, or implied volatility extrapolated from Seelos Therapeutics options trading.
Currently Active Assets on Macroaxis
When determining whether Seelos Therapeutics is a strong investment it is important to analyze Seelos Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Seelos Therapeutics' future performance. For an informed investment choice regarding Seelos Stock, refer to the following important reports:Check out the analysis of Seelos Therapeutics Correlation against competitors. For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Seelos Stock analysis
When running Seelos Therapeutics' price analysis, check to measure Seelos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seelos Therapeutics is operating at the current time. Most of Seelos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seelos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seelos Therapeutics' price. Additionally, you may evaluate how the addition of Seelos Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Seelos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seelos Therapeutics. If investors know Seelos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seelos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.73) | Revenue Per Share 0.45 | Return On Assets (1.80) | Return On Equity (5.84) |
The market value of Seelos Therapeutics is measured differently than its book value, which is the value of Seelos that is recorded on the company's balance sheet. Investors also form their own opinion of Seelos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seelos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seelos Therapeutics' market value can be influenced by many factors that don't directly affect Seelos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seelos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seelos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seelos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.